<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362139">
  <stage>Registered</stage>
  <submitdate>7/06/2012</submitdate>
  <approvaldate>10/07/2012</approvaldate>
  <actrnumber>ACTRN12612000739819</actrnumber>
  <trial_identification>
    <studytitle>A randomized, double-blind, placebo-controlled, dose-ranging pilot study of the efficacy and safety of GC811007 in subjects with type-2 diabetes mellitus and heart failure</studytitle>
    <scientifictitle>ADDUCE:  A randomized, double-blind, placebo-controlled, dose-ranging pilot study of the efficacy and safety of GC811007 in subjects with type-2 diabetes mellitus and heart failure: To assess safety and to determine whether treatment with GC811007 (400 and 1200 mg/day) improves exercise tolerance and indexes of cardiac structure and function</scientifictitle>
    <utrn />
    <trialacronym>ADDUCE: Assessment of a Drug for Diabetes and heart failUre using Cardiopulmonary Exercise - (ADDUCE - meaning ‘to cite as an example or proof’)</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type-2 diabetes mellitus</healthcondition>
    <healthcondition>Diabetes-associated heart failure</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with GC811007 (two treatment groups 400 and 1200 mg/day), supplied as multiples of 400mg capsules once per day over a six-month period, dose comparison versus placebo.</interventions>
    <comparator>Comparison of two different doses of GC811007 compared to placebo (supplied as microcrystalline cellulose in opaque Capsugel gelatin capsules)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary efficacy endpoint was the CPET (CardioPulmonary Exercise Testing) assessment of CHANGE IN TIME to reach 70% of peak oxygen consumption (VO2 max) determined by an incremental cycle exercise test, between baseline and Months 4 and 6.</outcome>
      <timepoint>Determined by an incremental cycle exercise test, between baseline and Months 4 and 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>CHANGE IN VO2 MAX between baseline and Month 4 and Month 6 as measured by CPET</outcome>
      <timepoint>Between baseline and  Month 4 and Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in left ventricular mass (LVM) and end systolic volume (LVESV) both indexed for BSA at Month 6 as measured by cardiac magnetic resonance imaging (cMRI)</outcome>
      <timepoint>At Month 6 as measured by cardiac magnetic resonance imaging (cMRI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Measurement of 24 hr urine trace element excretion including urine Cu.</outcome>
      <timepoint>Measured at baseline, Month 4 and Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in left ventricular mass (LVM) and end systolic volume (LVESV) at Month 6 as measured by cardiac magnetic resonance imaging (cMRI)</outcome>
      <timepoint>At Month 6 as measured by cardiac magnetic resonance imaging (cMRI)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men and women &gt; 20 years of age with type-2 diabetes mellitus and heart failure; must complette two CPET tests at baseline</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Healthy patients; subjects younger than 20 years; inability to complete 2 CPET tests at Baseline</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Dose comparison</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>13/07/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>93</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protemix Corporation</primarysponsorname>
    <primarysponsoraddress>Level 28, IAG House
151 Queen Street
Auckland 1010</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protemix Corporation</fundingname>
      <fundingaddress>Level 28, IAG House
151 Queen Street
Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A pilot study of subjects with type-2 diabetes mellitus and heart failure to determine whether treatment with two different doses of GC811007 improves exercise tolerance and indexes of cardiac structure and function; also to assess safety.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Health &amp; Disabilities Ethics Committee</ethicname>
      <ethicaddress>650 Great South Road, Auckland 1051, New Zealand</ethicaddress>
      <ethicapprovaldate>19/02/2004</ethicapprovaldate>
      <hrec>AKX/03/12/334</hrec>
      <ethicsubmitdate>1/11/2003</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Garth Cooper</name>
      <address>School of Biological Sciences
University of Auckland
Private Bag 92 019
Auckalnd 1142</address>
      <phone>+62 (9) 923 7239</phone>
      <fax />
      <email>g.cooper@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sally Poppitt</name>
      <address>School of Biological Sciences
University of Auckland
Private Bag 92 019
Auckalnd 1142</address>
      <phone>+64 (9) 630 5160</phone>
      <fax />
      <email>s.poppitt@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>